News >

Treatment Options for ALK+ NSCLC Continue to Grow

Ellie Leick
Published: Monday, Sep 16, 2019

Joseph Leach, MD, a medical oncologist at Minnesota Oncology

Joseph Leach, MD

As more systemic agents become available for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC), physicians are encouraged to test patients diagnosed with lung cancer for mutations, said Joseph Leach, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication